Eli Lilly & Co. (LLY) volatility elevated into Alzheimer's data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM ESTLeerink Partners analyst Seamus Fernandez lowered its price target on Eli Lilly (NYSE: LLY) to $92.00 (from $102.00) following the Sola failure but maintains a Outperform rating.
Fernandez commented, "LLY announced that solanezumab did not meet the primary endpoint in the Phase 3 EXPEDITION 3 study. Per our follow up... More
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM ESTBMO Capital downgraded Eli Lilly (NYSE: LLY) from Outperform to Market Perform with a price target of $64.00 (from $91).
Analyst Alex Arfaei commented, "We believe Solas failure in EXPEDITION-3 is clearly a meaningfully negative event as it significantly lowers Lillys long-term growth... More
Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM ESTLeerink Partners analyst Seamus Fernandez weighed in on Eli Lilly & Co. (NYSE: LLY) after sola failed, saying this makes the future of the company's AD portfolio uncertain.
Fernandez commeted, "This morning LLY announced that its EXPEDITION 3 trial of solanezumab (sola) did NOT... More
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM ESTEli Lilly & Co. (NYSE: LLY) CEO John Lechleite says there's no concern about the company's dividend, according to CNBC.
David A. Ricks. Senior Vice President and President, Lilly Bio-Medicines, also added that investors want the company to continue exploring solutions for Alzheimer's disease.
... MoreEli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM ESTEli Lilly & Co. (NYSE: LLY) falls 11% after the company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD).
... More
